Quick Answer
Connect Biopharma Holdings Ltd reported Net Income of -$55.48 million for fiscal year 2025.
Connect Biopharma Holdings Ltd Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$55.48M | -255.0% |
| 2024 | -$15.63M | +74.8% |
| 2023 | -$62.11M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$17.20M | -33.6% | -33.3% |
| June 30, 2025 | -$12.90M | -186.9% | -25.6% |
| March 31, 2025 | -$10.27M | -18.2% | +20.2% |
| September 30, 2024 | -$12.88M | — | -186.7% |
| June 30, 2024 | $14.85M | — | +270.8% |
| March 31, 2024 | -$8.69M | — | — |
- Connect Biopharma Holdings Ltd showed a decrease of -255.0% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, Connect Biopharma Holdings Ltd’s net income has grown by 10.7% (from -$62.11 million to -$55.48 million).
- The most recent figure is from Connect Biopharma Holdings Ltd’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: